Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial

作者：Kelly E. Seaton, Carmen A. Paez, Chenchen Yu, Shelly Karuna, Theresa Gamble, Maurine D. Miner, Jack Heptinstall, Lu Zhang, Fei Gao, Margaret Yacovone, Hans Spiegel, Julie B. Dumond, Maija Anderson, Estelle Piwowar-Manning, Bonnie J. Dye, India Tindale, Lori Proulx-Burns, Meg Trahey, Simbarashe Takuva, Azwidihwi Takalani, Veronique Bailey, Spyros A. Kalams, Hyman Scott, Nonhlanhla N. Mkhize, Joshua A. Weiner, Margaret E. Ackerman, M. Juliana McElrath, Michael Pensiero, Dan H. Barouch, David C. Montefiori, Georgia D. Tomaras, Lawrence Corey, Myron S. Cohen, Yunda Huang, Sharana Mahomed, Marc Siegel, Colleen F. Kelley · 发表于：The Lancet HIV · 年份：2025 · DOI：10.1016/s2352-3018(25)00012-8 · 被引用次数：6 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、Monoclonal and Polyclonal Antibodies Research